1Stitt AW, Jenkins AJ, Cooper ME. Advanced glycation end products and diabetic complications. Expert Opin Investig Drugs, 2002 , 11:1205-1223.
2Hou FF, Owen WF Jr. Beta 2-microglobulin amyloidosis: role of monocytes/macrophages. Curr Opin Nephrol Hypertens, 2002 ,11:417-421.
3Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Investig Dermatol Symp Proc, 2000 , 5:40-46.
4Sumpio BE, Riley JT, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol, 2002, 34:1508-1512.
5Bucciarelli LG, Wendt T, Rong L, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci, 2002 , 59:1117-1128.
6Stern DM, Yan SD, Yan SF, et al. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev, 2002 , 1:1-15.
7Stern D, Du Yan S, Fang Yan S, et al. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev, 2002, 54:1615-1625.
8Facchiano F, Lentini A, Fogliano V, et al. Sugar-induced modification of fibroblast growth factor 2 reduces its angiogenic activity in vivo. Am J Pathol, 2002, 161:531-541.
9Baumgartner-Parzer SM, Wagner L, Pettermann M, et al. High-glucose-triggered apoptosis in cultured endothelial cells. Diabetes, 1995, 44: 1323-1327.
10Mizuno K, Yamamura K, Yano K, et al. Effect of chitosan film containing basic fibroblast growth factor on wound healing in genetically diabetic mice. J Biomed Mater Res, 2003, 64:177-181.
